New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
17:11 EDTEXASExact Sciences' Cologuard shows 'unprecedented' rates of cancer detection
According to the Mayo Clinic, results of a clinical trial of Cologuard show unprecedented rates of precancer and cancer detection by a noninvasive test. The detection rates are similar to those reported for colonoscopy. The results were published in the March 20 issue of the New England Journal of Medicine. Cologuard was co-developed by Mayo Clinic and Exact Sciences. Cologuard, is a noninvasive sDNA test for the early detection of colorectal precancer and cancer. The clinical trial, called the DeeP-C study, included 10,000 patients and was designed to determine how well Cologuard detects precancer and cancer. The study also compared Cologuard to the fecal immunochemical test for occult blood. The study was conducted at 90 medical centers throughout the United States and Canada. According to the Mayo Clinic's website, the release is under embargo until March 19, at 5:00 pm ET, though it was visible on the "News Resources" section of the site. As of 5:00 pm ET on March 18, the post appeared to have been removed. Shares of Exact, which gained $1.29, or 9.82%, to close at $14.42 during today's session, are up an additional $1.09, or 7.56%, to $15.51 in after hours trade. Reference Link
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
11:37 EDTEXASHigh option volume stocks
Subscribe for More Information
July 22, 2014
14:39 EDTEXASExact Sciences Cologuard to be approved in August or September, says Mizuho
Subscribe for More Information
07:37 EDTEXASExact Sciences reports Q2 EPS (24c), consensus (25c)
Exact reported total revenues of $0.0 million for the second quarter of 2014, compared to $1.0 million for the second quarter of 2013.
07:08 EDTEXASLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use